Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-reboxetine administered once daily in patients with fibromyalgia

Trial Profile

An 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-reboxetine administered once daily in patients with fibromyalgia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Fibromyalgia; Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Aug 2023 According to Axsome Therapeutics media release, company now expects to submit the NDA in the fourth quarter of 2023 or the first quarter of 2024
    • 01 Mar 2022 According to Axsome Therapeutics media release, company expects to submit the NDA for AXS-14 for the management of fibromyalgia in 2023.
    • 15 Jun 2021 According to Axsome Therapeutics media release, based on results from this trial and CTP: 30906 the company announced its plan to submit a NDA for AXS-14 for the management of fibromyalgia following a pre-NDA meeting with the U.S. FDA. The NDA submission is currently anticipated in the fourth quarter of 2022 pending successful completion of manufacturing and other activities related to the product candidate. Acceptance of the NDA will be subject to the FDA's review of complete filing.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top